Tuesday, December 5, 2023
Diabetic kidney disease (DKD) leads to complications that include end-stage renal disease (ESRD), cardiovascular disease, infection, and death. For the first time in decades, the FDA approved the sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin for the treatment of DKD in patients with type 2 diabetes (T2D). Additionally, accumulating data from the SGLT2 inhibitor class are informing clinicians on the need to individualize treatment. This online curriculum will provide expert perspectives from nephrologists, endocrinologists, primary care providers (PCPs), and cardiologists on the increasing role of SGLT2 inhibitors beyond glucose control.
Supported by an independent educational grant from
Janssen Pharmaceuticals, Inc.
Developed through a collaboration between the University of Chicago Medicine and Medscape Education.
Access relevant slides on incidence, identification, and emerging treatment strategies for DKD in T2D.
Download
Steering Committee Chair
Professor of Medicine
Director
AHA Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, Illinois, United States
Professor of Medicine
Indiana University School of Medicine
Indianapolis, Indiana, United States
The Frist Clinic
Nashville, Tennessee, United States
Clinical Professor of Medicine
University of California at San Diego
San Diego, California, United States
Scientia Professor of Medicine
George Institute
UNSW Sydney
Sydney, Australia
Clinical Professor of Medicine
University of Washington
Spokane, Washington, United States
Steering Committee Chair
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Janssen Pharmaceuticals; KBP Biosciences Co., Ltd.; Merck & Co., Inc.; Novo Nordisk; Relypsa, Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Akebia; AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo, Inc.; Genzyme Corporation; GlaxoSmithKline; Ironwood Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Lilly USA, LLC; Reata Pharmaceuticals, Inc.; Relypsa, Inc.; Sanofi; Takeda Pharmaceuticals North America, Inc.; ZS Pharma
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Lilly USA, LLC; MannKind Corporation; Merck & Co., Inc.; Novo Nordisk; Sanofi
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Janssen Pharmaceuticals; Lilly USA, LLC; Novo Nordisk; Sanofi
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Janssen Pharmaceuticals
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Lilly USA, LLC
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AbbVie Inc.; Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Baxter; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Dimerix; Durect Corporation; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals; Lilly USA, LLC; Merck & Co., Inc.; Metavant Sciences; Mitsubishi Tanabe Pharma Corporation; Mundipharma; Novartis Pharmaceuticals Corporation; Novo Nordisk; Pfizer Inc.; PharmaLink; Relypsa, Inc.; Retrophin, Inc.; Sanofi; SERVIER; Tricida, Inc.; Vifor Pharma
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Baxter; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Dimerix; Durect Corporation; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals; Lilly USA, LLC; Merck & Co., Inc.; Metavant Sciences; Mitsubishi Tanabe Pharma Corporation; Mundipharma; Novartis Pharmaceuticals Corporation; Novo Nordisk; Pfizer Inc.; PharmaLink; Relypsa, Inc.; Retrophin, Inc.; Sanofi; SERVIER; Tricida, Inc.; Vifor Pharma
Received grants for clinical research from: Janssen Pharmaceuticals; Pfizer Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Abbott Laboratories; Dexcom, Inc.; Janssen Pharmaceuticals; Novo Nordisk; Sanofi
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Dexcom, Inc.; Janssen Pharmaceuticals; Novo Nordisk; Sanofi